Onesource Specialty Pharma Ltd — earnings calls
1 quarter summarised from transcripts filed with the exchange, every statement cited. Newest first.
A withheld summary was generated but did not pass Parakho's publication checks; nothing that fails a check is shown. How we check these summaries
OneSource reported a sequential recovery in Q4 FY26 with revenue of INR4,282 million, up 47% quarter-over-quarter, driven by the India Semaglutide launch and broad-based improvement across service lines. EBITDA rose more than 5x sequentially to INR919 million, while full-year revenue declined 2% and EBITDA declined about 35% year-on-year due to delayed Semaglutide approvals in Canada earlier in the year. Management reiterated its FY28 guidance of US$400 million organic revenue with around 40% EBITDA margin and confirmed the Steriscience/Brooks scheme has been deferred following shareholder concerns on valuation.